第 42 卷第 5 期 |  | Vol. 42 No. 5 | 2012 年 10 月 | Oct 2012 |
|
所屬欄目:醫藥及中間體
聚腺苷二磷酸核糖聚合酶抑制劑Rucaparib的合成研究 |
耿元碩,胡 珀,王 欣,劉 超,李志裕*
(中國藥科大學(xué) 藥物化學(xué)教研室,江蘇 南京 210009) |
摘 要:Rucaparib是首個(gè)進(jìn)入臨床實(shí)驗的聚腺苷二磷酸核糖聚合酶(PARP)抑制劑。筆者以5-氟-2-甲基苯甲酸為起始原料經(jīng)過(guò)12步反應得到Rucaparib。這是一條安全低毒、操作簡(jiǎn)易的全新合成路線(xiàn),總收率達5.38%,其中間體及最終產(chǎn)物結構均經(jīng)過(guò)MS和1H NMR確證。 |
關(guān)鍵詞:PARP抑制劑;Rucaparib;合成 |
中圖分類(lèi)號:R737.902 文獻標識碼:A 文章編號:1009-9212(2012)05-0048-05 |
|
Synthesis of Rucaparib——A Poly(ADP-ribose)Polymerase Inhibitor |
GENG Yuan-shuo,HU Po,WANG Xin,LIU Chao,LI Zhi-yu*
(Department of Medicinal Chemistry,China Pharmaceutical University,Nanjing 210009,China) |
Abstract:Rucaparib is the first PARP inhibitor which entered into the clinical trial. It was prepared in 5.38% overall yield in 12 steps by using 5-fluoro-2-methylbenzoic acid as the starting material. The synthetic process was designed as a novel method with less toxicity and easy operation. The structures of the intermediates and the final product were identified with MS and 1H NMR. |
Key words:PARP inhibitors;Rucaparib;synthesis |
|
基金項目:中央高;究蒲袠I(yè)務(wù)費專(zhuān)項資金資助(JKY2011062)。
|
作者簡(jiǎn)介:耿元碩(1986-),男,江蘇鹽城人,碩士,主要從事抗腫瘤藥物分子的設計與合成。(E-mail:gengys2010@126.com)
|
聯(lián) 系 人:李志裕,教授,碩士研究生導師。(E-mail:zhiyuli@cpu.edu.cn)
|
收稿日期:2012-10-12
|
|